Junlin Ho J.D. Net Worth

The estimated Net Worth of Junlin Ho is at least 1.94 百万$ dollars as of 17 June 2024. Ms Ho owns over 4,695 units of Scholar Rock Corp stock worth over 1,773,420$ and over the last 3 years she sold SRRK stock worth over 163,761$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms D SRRK stock SEC Form 4 insiders trading

Ms has made over 3 trades of the Scholar Rock Corp stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 4,695 units of SRRK stock worth 42,161$ on 17 June 2024.

The largest trade she's ever made was selling 4,695 units of Scholar Rock Corp stock on 17 June 2024 worth over 42,161$. On average, Ms trades about 1,237 units every 15 days since 2022. As of 17 June 2024 she still owns at least 204,076 units of Scholar Rock Corp stock.

You can see the complete history of Ms Ho stock trades at the bottom of the page.

Ms. Junlin Ho J.D. biography

Junlin Ho J.D. is the Gen. Counsel & Corp. Sec. at Scholar Rock Corp.

How old is Ms D?

Ms D is 42, she's been the Gen. Counsel & Corp. Sec. of Scholar Rock Corp since . There are 13 older and no younger executives at Scholar Rock Corp. The oldest executive at Scholar Rock Holding Corp is Michael Gilman, 65, who is the Independent Director.

Insiders trading at Scholar Rock Corp

Over the last 6 years, insiders at Scholar Rock Corp have traded over 8,613,447$ worth of Scholar Rock Corp stock and bought 8,895,194 units worth 64,726,758$ . The most active insiders traders include Timothy A Springer、Srinivas Akkaraju、Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of 1,953,616$. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth 13,538$.

What does Scholar Rock Corp do?

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s

Complete history of Ms Ho stock trades at Scholar Rock Corp

Scholar Rock Corp executives and stock owners

Scholar Rock Corp executives and other stock owners filed with the SEC include:

• Dr. Nagesh K. Mahanthappa MBA, Ph.D.,
  Interim CEO & Director
• Yung Chyung,
  Chief Medical Officer
• Alan Buckler,
  Chief Scientific Officer
• Edward H. Myles M.B.A., MBA,
  CFO & Head of Bus. Operations
• Dr. Gregory John Carven Ph.D.,
  Chief Scientific Officer
• David Hallal,
  Independent Chairman of the Board
• Michael Gilman,
  Independent Director
• Kristina Burow,
  Independent Director
• Edward Myles,
  Chief Financial Officer
• Tony Kingsley,
  President, Chief Executive Officer, Director
• Erin Moore,
  Senior Vice President - Finance
• Catherine Hu,
  IR Contact Officer
• Ryan Iarrobino,
  Sr. VP of Clinical Devel. & Operations
• Erin Moore,
  Sr. VP of Fin.
• Dr. George G. Nomikos M.D., Ph.D.,
  Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
• Lisa Amaya Price,
  Sr. VP of HR
• Dr. Yung H. Chyung M.D.,
  Chief Medical Officer
• Caryn Parlavecchio,
  Chief HR Officer
• Junlin Ho J.D.,
  Gen. Counsel & Corp. Sec.
• Public Equities, L.P.Artal ...,
  
• Stuart A Kingsley,
  President and CEO
• Richard Brudnick,
  
• Bio Capital Gp, Llc Samsara...,
  
• Srinivas Akkaraju,
  
• Venture Management Co. Vi, ...,
  
• Rhonda M. Chicko,
  Chief Financial Officer
• Elan Ezickson,
  COO & Head of Corp.Development
• Venture Fund Viii, L.P.Arch...,
  
• International S.C.A.Invus P...,
  
• Jeffrey S. Flier,
  
• Katie Peng,
  
• Jay T. Backstrom,
  CHIEF EXECUTIVE OFFICER
• Timothy A Springer,
  10% owner
• Mo Qatanani,
  CHIEF SCIENTIFIC OFFICER
• Tracey Sacco,
  CHIEF COMMERCIAL OFFICER
• Jing L. Marantz,
  CHIEF MEDICAL OFFICER
• Joshua Reed,
  
• Akshay Vaishnaw,
  
• Gregory John Carven,
  Chief Scientific Officer
• Amir Nashat,
  
• Nagesh K. Mahanthappa,
  Interim CEO and President
• Public Equities, L.P.Artal ...,
  
• Junlin Ho,
  GENERAL COUNSEL
• Caryn Parlavecchio,
  CHRO